Format

Send to

Choose Destination
See comment in PubMed Commons below
Front Biosci (Landmark Ed). 2009 Jan 1;14:2983-95.

Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes.

Author information

1
Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO 63110, USA. imaishin@wustl.edu

Abstract

Both genetic and environmental factors contribute to the pathogenesis of type 2 diabetes, and it is critical to understand the interplay between these factors in the regulation of insulin secretion and insulin sensitivity to develop effective therapeutic interventions for type 2 diabetes. For the past several years, studies on the mammalian NAD-dependent protein deacetylase SIRT1 and systemic NAD biosynthesis mediated by nicotinamide phosphoribosyltransferase (NAMPT) have demonstrated that these two regulatory components together play a critical role in the regulation of glucose homeostasis, particularly in the regulation of glucose-stimulated insulin secretion in pancreatic beta cells. These components also contribute to the age-associated decline in beta cell function, which has been suggested to be one of the major contributing factors to the pathogenesis of type 2 diabetes. In this review article, the roles of SIRT1 and NAMPT-mediated systemic NAD biosynthesis in glucose homeostasis and the pathophysiology of type 2 diabetes will be summarized, and their potential as effective targets for the treatment and prevention of type 2 diabetes will be discussed.

PMID:
19273250
PMCID:
PMC2734392
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Frontiers in Bioscience Icon for PubMed Central
    Loading ...
    Support Center